ACACIA RESEARCH CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ACACIA RESEARCH CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $12.00M | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $4.38M | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | $19.47M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $2.12M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $3.82M | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $688.0K | Mar 29, 2021 |
| FY2020 | Sep 30, 2019 | $1.71M | Mar 29, 2021 |
| FY2020 | Jun 30, 2019 | $5.46M | Mar 29, 2021 |
| FY2020 | Mar 31, 2019 | $3.39M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $49.20M | Mar 16, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $285.23M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $122.31M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $125.10M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $59.22M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $88.05M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $29.78M | Mar 31, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.48M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $29.65M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $72.27M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $21.84M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $51.95M | Mar 17, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.68M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($36.06M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $67.06M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($125.07M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $149.20M | Mar 17, 2023 |
| FY2021 | Sep 30, 2021 | ($55.05M) | Mar 31, 2022 |
| FY2021 | Jun 30, 2021 | ($144.81M) | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | ($164.47M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $80.24M | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | $38.35M | Mar 29, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.41M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($32.93M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $20.94M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($40.09M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $14.55M | Mar 17, 2023 |
| FY2020 | Dec 31, 2020 | ($6.42M) | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | ($2.78M) | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | ($6.75M) | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | ($3.57M) | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | ($7.43M) | Mar 29, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $37.0K | Mar 17, 2025 |
| FY2023 | Dec 31, 2023 | $735.0K | Mar 15, 2024 |
| FY2023 | Dec 31, 2022 | $626.0K | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $200.0K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.24M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $50.12M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($22.51M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($37.34M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $13.33M | Mar 17, 2023 |
| FY2021 | Sep 30, 2021 | ($7.60M) | Mar 31, 2022 |
| FY2021 | Jun 30, 2021 | ($6.20M) | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | ($6.12M) | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($19.62M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.31M) | Mar 29, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $148.67M | Mar 17, 2025 |
| FY2024 | Dec 31, 2023 | $189.0K | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $732.0K | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $91.0K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $199.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $183.0K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $34.0K | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $2.0K | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $4.0K | Mar 7, 2018 |
| FY2017 | Dec 31, 2015 | $8.0K | Mar 7, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $770.96M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $756.39M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $633.55M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $482.93M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $798.86M | Mar 17, 2023 |
| FY2021 | Sep 30, 2021 | $746.08M | Mar 31, 2022 |
| FY2021 | Jun 30, 2021 | $623.83M | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | $564.90M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $511.31M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $218.16M | Mar 29, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.92M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $203.78M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $43.94M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $193.68M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $353.63M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $212.07M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $35.11M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $32.71M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $13.11M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $28.56M | Mar 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $543.45M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $514.83M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $568.27M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $258.28M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $419.43M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $277.27M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $173.13M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $189.39M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $294.30M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $265.59M | Mar 7, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.79M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $29.34M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $8.99M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $7.54M | Mar 17, 2025 |
| FY2022 | Dec 31, 2021 | $7.47M | Mar 17, 2023 |
| FY2022 | Dec 31, 2020 | $0 | Mar 17, 2023 |
| FY2017 | Dec 31, 2015 | $30.10M | Mar 7, 2018 |
| FY2016 | Dec 31, 2014 | $30.10M | Mar 10, 2017 |
| FY2014 | Dec 31, 2013 | $30.15M | Mar 2, 2015 |
| FY2013 | Dec 31, 2012 | $30.15M | Mar 3, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($254.10M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($275.79M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($239.73M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($306.79M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($181.72M) | Mar 17, 2023 |
| FY2021 | Sep 30, 2021 | ($385.97M) | Mar 31, 2022 |
| FY2021 | Jun 30, 2021 | ($475.73M) | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | ($495.39M) | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($330.92M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($439.66M) | Mar 29, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $306.72M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $273.88M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $340.09M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $287.79M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $308.94M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $165.55M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $57.36M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $128.81M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $136.60M | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | $139.05M | Mar 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.90M | Mar 12, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 2 | Mar 17, 2023 |
| FY2021 | Sep 30, 2021 | (1) | Mar 31, 2022 |
| FY2021 | Jun 30, 2021 | (3) | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | (2) | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | 1 | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 29, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 1 | Mar 17, 2023 |
| FY2021 | Sep 30, 2021 | (1) | Mar 31, 2022 |
| FY2021 | Jun 30, 2021 | (3) | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | (2) | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | 1 | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 29, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 96.48M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 96.05M | Mar 12, 2026 |
| FY2025 | Jul 1, 2024 | 99.89M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 99.90M | Mar 17, 2025 |
| FY2023 | Jul 31, 2023 | 99.89M | Mar 15, 2024 |
| FY2023 | Dec 31, 2022 | 43.48M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 48.81M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 49.28M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 50.37M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 49.64M | Mar 16, 2020 |